Abstract 213P
Background
Renal cell carcinoma with sarcomatoid de-differentiation (sRCC) is a highly aggressive form RCC with trials reporting a poor median OS of 5 to 12 months. Recent genomics profiling of sRCC suggest that Srcc is not a single entity but is highly influenced by the parent RCC subtype from which its shares histological characteristic. A recent meta-analysis suggests that sRCC is associated with a higher cancer specific mortality, poorer progression free and overall survival but not gender and average age. A population-based study of 879 patients taken from the SEER data showed that the 5-year DSS were 77.7%, 67.8%, 35.4%, and 3.5% for patients with stage I, II, III, and IV disease at diagnosis.
Methods
A retrospective analysis was conducted on patients diagnosed with sRCC from 1997 to 2018. Disease characteristics, treatment outcomes and adverse events were retrieved from digital medical records. Overall survival and progression free survival were estimated using Kaplan Meier method.
Results
62 patients with a diagnosis of sRCC were identified. 72% (n = 45) were males. Median age was 56 years old on diagnosis. Majority of patients were Chinese at 72%. 52%(N = 32) were metastatic on diagnosis with 18%(n = 12) were diagnosed with initially early stages(I-II). 80%(n = 47) were symptomatic from the cancer on diagnosis with at least 1 symptom of haematuria, flank pain, fever, loss of weight. Majority of the patients (n = 54) had were clear cell rcc with sarcomatoid component while the 7% (n = 5) were papillary rcc. The median overall survival for the metastatic group was 1.26 years with 53% having had VEGF inhibitors as first line treatment while about a quarter had no treatment.
Conclusions
We currently report the disease characteristics and treatment of patients diagnosed with sRCC in our tertiary cancer centre. In our study, about half of the cohort was metastatic on diagnosis with another 20% having early stage on initial diagnosis. The overall survival outcomes of this real world metastatic sRCC group is promising and appears better than prior reports. More research is needed to better understand this group of patients with poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ravindran Kanesvaran.
Funding
Has not received any funding.
Disclosure
R. Kanesvaran: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Johnson and Johnson. All other authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract